<DOC>
	<DOC>NCT01974232</DOC>
	<brief_summary>This is a retrospective analysis of children (â‰¤21years old) who received clinical treatment with either Romiplostim or Eltrombopag at 2 medical centers from 2009-2013. The children included in this study were from Weill Medical College of Cornell University, New York, New York and Children's Hospital Orange County, Orange, California</brief_summary>
	<brief_title>A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag From 2009-2013</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
	<criteria>1. All patients in this study had received prior treatments before the start of TPO treatment including corticosteroids, IVIG, IV antiD, and/or Rituximab. 1. Children who do not have ITP</criteria>
	<gender>All</gender>
	<minimum_age>19 Months</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Immune Thrombocytopenia (ITP), Thrombopoietin (TPO) agents, children, romiplostim and eltrombopag</keyword>
</DOC>